300149 睿智医药
2026/09 - 九个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-1.0231.077-17.089-48.47716.827
总资产报酬率 ROA (%)-0.6370.666-10.224-29.3729.037
投入资产回报率 ROIC (%)-0.7190.748-11.502-32.93910.070

边际利润分析
销售毛利率 (%)25.90728.61521.80025.93525.423
营业利润率 (%)-1.0922.035-22.350-82.25556.350
息税前利润/营业总收入 (%)1.2172.248-23.476-81.32255.826
净利润/营业总收入 (%)-1.4031.194-23.347-80.54927.320

收益指标分析
经营活动净收益/利润总额(%)47.164113.54226.5216.392-11.315
价值变动净收益/利润总额(%)9.68875.911-3.3650.098190.871
营业外收支净额/利润总额(%)14.786-44.1866.3920.362-2.575

偿债能力分析
流动比率 (X)1.9892.1521.8581.7041.749
速动比率 (X)1.9492.1261.8251.6391.691
资产负债率 (%)36.78236.03637.96739.98837.762
带息债务/全部投入资本 (%)12.16510.27310.54610.32915.544
股东权益/带息债务 (%)576.781686.166648.516643.036443.387
股东权益/负债合计 (%)168.084174.180160.194147.585163.121
利息保障倍数 (X)0.4872.687-58.773-66.00862.684

营运能力分析
应收账款周转天数 (天)74.24964.40081.73895.71891.814
存货周转天数 (天)5.1474.6479.32915.09420.310